1Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, and.
2The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
J Neurosurg. 2019 Sep 1;131(3):657-666. doi: 10.3171/2019.5.JNS181762.
The last decade has seen a crescendo of FDA approvals for immunotherapies against solid tumors, yet glioblastoma remains a prominent holdout. Despite more than 4 decades of work with a wide range of immunotherapeutic modalities targeting glioblastoma, efficacy has been challenging to obtain. Earlier forms of immune-based platforms have now given way to more current approaches, including chimeric antigen receptor T-cells, personalized neoantigen vaccines, oncolytic viruses, and checkpoint blockade. The recent experiences with each, as well as the latest developments and anticipated challenges, are reviewed.
过去十年，FDA 批准了许多针对实体瘤的免疫疗法，但胶质母细胞瘤仍然是一个突出的例外。尽管 40 多年来，人们采用了广泛的免疫治疗方法来靶向胶质母细胞瘤，但疗效却难以获得。早期形式的免疫平台现在已经让位于更现代的方法，包括嵌合抗原受体 T 细胞、个性化新抗原疫苗、溶瘤病毒和检查点阻断。本文综述了每种方法的最新经验，以及最新的发展和预期的挑战。
